Belvedere Trading’s Larimar Therapeutics LRMR Stock Holding History

Belvedere Trading’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-22,954	Closed	-$276K	–	545
2021 Q3	$276K	Buy	+22,954	New	+$275K	0.01%	198

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Belvedere Trading's LRMR Position: Q4 2021 in Review

Belvedere Trading sold out of Larimar Therapeutics (LRMR) in Q4 2021, closing a stake of 22,954 shares — an estimated $276K sold.

Belvedere Trading first reported a position in LRMR in Q3 2021 and held it in 1 quarter. The position peaked at $276K in Q3 2021. 49 funds tracked by Wall St. Rank hold LRMR as of Q4 2021.

Belvedere Trading reported no remaining Larimar Therapeutics position as of Q4 2021 after selling out during the quarter.
Belvedere Trading sold 22,954 Larimar Therapeutics shares in Q4 2021, an estimated $276K.
Belvedere Trading first reported a position in Larimar Therapeutics in Q3 2021 and held it in 1 quarter.
Belvedere Trading's Larimar Therapeutics position peaked at $276K in Q3 2021.
49 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.